(Total Views: 232)
Posted On: 01/04/2019 1:45:37 PM
Post# of 36566
This is the kind of thing that makes me skeptical and optimistic at the same time. From SA.
A combination trial evaluating Merck's (MRK +2.9%) Keytruda (pembrolizumab) and peptide vaccine AE37 in metastatic triple-negative breast cancer is advancing. Site selection is underway, study drugs are being packaged and the Institutional Review Board is reviewing the protocol.
Generex has initiated partnering discussions for co-development and collaborative R&D opportunities in I-O and immunotherapies.
These two bullet points are posted on SA in this order. Merck is referenced as a combination partner in the first point and "partnering discussions for co-development and collaborative R&D opportunities in I-O and immunotherapies" is referenced in the next point.
This could easily be misinterpreted that Merck may be discussing partnership with Antigen Express. There is nothing dishonest or misleading, but sometimes enthusiasm causes one plus one to equal three.
A combination trial evaluating Merck's (MRK +2.9%) Keytruda (pembrolizumab) and peptide vaccine AE37 in metastatic triple-negative breast cancer is advancing. Site selection is underway, study drugs are being packaged and the Institutional Review Board is reviewing the protocol.
Generex has initiated partnering discussions for co-development and collaborative R&D opportunities in I-O and immunotherapies.
These two bullet points are posted on SA in this order. Merck is referenced as a combination partner in the first point and "partnering discussions for co-development and collaborative R&D opportunities in I-O and immunotherapies" is referenced in the next point.
This could easily be misinterpreted that Merck may be discussing partnership with Antigen Express. There is nothing dishonest or misleading, but sometimes enthusiasm causes one plus one to equal three.
(0)
(0)
